Leerink raised the firm’s price target on Avidity Biosciences to $56 from $38 and keeps an Outperform rating on the shares. The firm notes Avidity presented positive and consistent data across multiple biomarkers and functional outcomes from the Phase 1/2 FORTITUDE study of AOC 1020 in facioscapulohumeral muscular dystrophy, even at the first and lowest dose tested, which sent the stock up about 30% on Wednesday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences: Promising Trials and Strategic Growth Initiatives
- Biotech Alert: Searches spiking for these stocks today
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Bank of America Predicts up to ~200% Surge for These 2 ‘Strong Buy’ Stocks
- Avidity Biosciences Welcomes Simona Skerjanec as New Director